| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial DW Lee, JN Kochenderfer, M Stetler-Stevenson, YK Cui, C Delbrook, ... The Lancet 385 (9967), 517-528, 2015 | 3335 | 2015 |
| Tumor in the crossfire: inhibiting TGF-β to enhance cancer immunotherapy NP Tschernia, JL Gulley BioDrugs 36 (2), 153-180, 2022 | 39 | 2022 |
| Characterization of naturally-occurring humoral immunity to AAV in sheep J Tellez, K Van Vliet, YS Tseng, JD Finn, N Tschernia, G Almeida-Porada, ... PLoS One 8 (9), e75142, 2013 | 26 | 2013 |
| Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplantation for acute myelogenous leukemia NP Tschernia, V Kumar, DT Moore, BG Vincent, CC Coombs, ... Transplantation and Cellular Therapy 27 (12), 1021. e1-1021. e5, 2021 | 20 | 2021 |
| Society for immunotherapy of cancer clinical and biomarkers data sharing resource document: volume I—conceptual challenges S Rutella, MA Cannarile, S Gnjatic, B Gomes, J Guinney, V Karanikas, ... Journal for immunotherapy of cancer 8 (2), 2020 | 12 | 2020 |
| CAR T cells reach clinical milestone in prostate cancer NP Tschernia, SM Norberg, JL Gulley Nature Medicine 28 (4), 635-636, 2022 | 8 | 2022 |
| Intent-to-treat results of a Phase I trial of CD19 chimeric antigen receptor engineered T cells using a consistent treatment regimen reveals a 67% complete response rate in … DW Lee, M Stetler-Stevenson, M Sabatino, C Yuan, TJ Fry, NN Shah, ... Blood 124 (21), 381, 2014 | 8 | 2014 |
| A phase I single-arm study of biweekly NHS-IL12 in patients with metastatic solid tumors ME Gatti-Mays, NP Tschernia, J Strauss, RA Madan, FH Karzai, M Bilusic, ... The oncologist 28 (4), 364-e217, 2023 | 7 | 2023 |
| Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas NP Tschernia, H Heiling, AM Deal, C Cheng, C Babinec, M Gonzalez, ... Journal for Immunotherapy of Cancer 11 (8), 2023 | 7 | 2023 |
| Non-relapse mortality in TP53-mutated MDS/AML-a multi-center collaborative study MT Byrne, TJ Kurian, DA Patel, R Tamari, S Hong, H Abdelhakim, V Klein, ... Blood 138, 2922, 2021 | 7 | 2021 |
| Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors NS Grover, N Tschernia, G Dotti, B Savoldo Journal of Clinical Oncology 39 (5), 499-513, 2021 | 6 | 2021 |
| Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12 NJ Toney, ME Gatti-Mays, NP Tschernia, J Strauss, JL Gulley, J Schlom, ... International immunopharmacology 116, 109736, 2023 | 5 | 2023 |
| Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges A Cesano, MA Cannarile, S Gnjatic, B Gomes, J Guinney, V Karanikas, ... Journal for immunotherapy of cancer 8 (2), 2020 | 5 | 2020 |
| Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) PJ Meacham, ALM Williams, M Strawderman, AM Baran, WJ Archibald, ... Leukemia & Lymphoma 61 (7), 1636-1644, 2020 | 2 | 2020 |
| Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors N Tschernia, R Orentas, C Mackall Journal for ImmunoTherapy of Cancer 2, 1-2, 2014 | 2 | 2014 |
| 508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition D Bortone, A Monette, N Tschernia, A Cogdill, Y Najjar, RF Sweis, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| A Multi-Center Collaborative Study of Outcomes of TP53-Mutatedmds/AML Patients Following Allogeneic HCT M Byrne, T Kurian, D Patel, R Tamari, S Hong, H Abdelhakim, V Klein, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | 1 | 2022 |
| A Head Start: CAR-T Cell Therapy for primary malignant brain tumors NP Tschernia, S Khagi Current Treatment Options in Oncology 21, 1-18, 2020 | 1 | 2020 |
| T cells engineered to express a chimeric antigen receptor targeting chondroitin sulfate proteoglycan 4 (CSPG4) specifically kill medulloblastoma and produce inflammatory cytokines CM Rota, N Tschernia, S Feldman, C Mackall, DW Lee Cancer Research 75 (15_Supplement), 3151-3151, 2015 | 1 | 2015 |
| 1470 START001: a phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid … JL Gulley, RJ Sullivan, CF Friedman, GP Sonpavde, NP Tschernia, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 3), 2024 | | 2024 |
